Pharmacovigilance and Related Developments 2011-2021

NEW YORK, Sept. 27, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Pharmacovigilance and Related Developments 2011-2021

http://www.reportlinker.com/p0629364/Pharmacovigilance-and-Related-Developments-2011-2021.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=NoCategory

Report Details

What does the future hold for pharmacovigilance? Visiongain's new report shows you prospects to 2021, discussing opportunities and developments. Find data you need.

Assess events, opportunities and activities shaping pharmacovigilance to 2021: regulations, technologies and services. Through our research and analysis we aim to save you time and help in your decisions.

How will changes affect pharmacovigilance? What are drug producers and service providers doing? What regulations and technologies influence that field? Our study explains, showing you developments and opportunities.

Pharmacovigilance will become more important during this decade. You can discover spending forecasts for pharmacovigilance. Find data and discussions for the overall world market, the US, the EU and Japan.

Discover pharmacovigilance activities of Pfizer, J&J, GSK, Sanofi, Novartis, AstraZeneca, Roche, Abbott, Eli Lilly and Bristol-Myers Squibb. You can find trends and prospects.

Assess leading companies offering pharmacovigilance services - Oracle, Aris Global, NDA, PharSafer Associates and PrimeVigilance. See what activities are shaping the field.

Our new report provides data, analysis and opinion to benefit your research, calculations, meetings and presentations. To get that information please respond now.

Analysis with potential future trends, revenue predictions, opinions and discussions

In our report you find revenue forecasts, growth rates, market shares, qualitative analyses, opinions from our survey and discussions of regulations and companies. You receive 56 tables and charts and three research interviews (see the accompanying lists).

Pharmacovigilance and Related Developments 2011-2021 shows you opportunities, challenges and forecasts

Our report gives you the following advantages in particular:

• Receive wide-ranging data and discussions for pharmacovigilance, seeing the relevance of regulations and practices

• Assess the activities of top pharma companies and leading service providers

• Discover a forecast for world pharmacovigilance spending to 2021, seeing trends

• Find pharmacovigilance spending forecasts to 2021 for the US, the EU and Japan

• Receive a forecast to 2021 for R&D spending in the world pharma industry

• Investigate driving and restraining forces in pharmacovigilance, seeing opportunities

• Assess the implications of pharmacovigilance for stakeholders - drug manufacturers, pharma regulators, prescribers, payers and patients

• View opinion from our survey of the industry, with three full interview transcripts.

There, you find a distinctive mix of quantitative and qualitative analysis with independent predictions. We tackle crucial questions in pharmacovigilance, helping you to stay ahead.

Order our report now to gain industry and market analysis for pharmacovigilance

Our report is for everybody needing industry and market analysis for pharmacovigilance. Find trends and answers. Avoid missing out - please order our report now.

Visiongain is a trading partner with the US Federal Government

CCR Ref number: KD4R6 

Companies Listed

Abbott Laboratories

Acorda Therapeutics

Agencia Nacional de Vigilancia Sanitaria [Brazil]

Alexion Europe SAS

Aris Global

Asia-Pacific Economic Cooperation (APEC)

Association of British Pharmaceutical Industries (ABPI)

Association of British Pharmaceutical Industries' Pharmacovigilance Expert Network

Association of the Southeast Asian Nations (ASEAN)

AstraZeneca 

Brazilian Health Surveillance Agency [Brazil] 

Bristol-Myers Squibb

Bureau of Pharmaceutical Affairs (Department of Health) [Chinese Taipei]

Center for Biologics Evaluation and Research (CBER) [USA]

Center for Devices and Radiological Health (CDRH) [USA]

Centers for Disease Control and Prevention

Center for Drug Evaluation and Research (CDER) [USA]

Center for Food Safety and Applied Nutrition (CFSAN) [USA]

Center for Veterinary Medicine (CVM) [USA]

Cerner Galt

ClinicalTrials 

Commission on Human Medicines

Committee for Medicinal Products for Human Use (CHMP)

Committee on the Safety of Medicine

Contergan Foundation

Council for International Organization of Medical Sciences

Covectra

Department of Drug Registration (State Food and Drug Administration) [China]

Department of Health and Ageing [Australia]

Department of International Cooperation (State Food of Drug Administration) [China]

Division of Medical Products Registration [Russia]

Division of Pharmaceutical Chemistry (Department of Health) [Chinese Taipei] 

Drug Evaluation Department (Korea Food and Drug Administration [KFDA]) [South Korea]

Drug Logic

Drug Safety Research Unit

Eli Lilly 

Elliot Brown Consulting

Eudravigilance Database

European Commission

European Council

European Economic Area

European Federation of Pharmaceutical Industries and Associations (EFPIA) 

European Free Trade Association 

European Pharmacovigilance Guidelines

European Medicines Agency (EMA)

European Medicines Evaluation Agency

European Parliament 

Federal Association of Thalidomide Victims

Federal Service on Surveillance in Healthcare and Social Development [Russia]

Food and Drug Administration (US FDA)

Food and Drug Administration Sentinel Initiative

Genentech 

GlaxoSmithKline (GSK)

Grünenthal

Gulf Cooperation Council (GCC)

Health Products Regulation Group (Health Sciences Authority) [Singapore]

Health Sciences Authority [Singapore]

Homeland Security Advisory System

Human Genome Project

ICH Global Cooperation Group

iGuard 

Imperial Chemical Industries (ICI)

Imperial College London

Innovative Medicines Initiative 

Intensive Medicine s Monitoring Programme

International Conference on Harmonisation (ICH)

Ion Torrent

Japan Pharmaceutical Manufacturers Association (JPMA)

Johnson & Johnson 

J-PEM

Korea Food and Drug Administration [South Korea]

Medicines and Healthcare Products Regulatory Agency (MHRA)

Medicines Monitoring Programme

MediGuard

MedWatch

MedImmune Patient Safety 

Merck & Co.

Ministry of Health and Welfare [India]

Ministry of Health, Labour and Welfare (MHLW) [Japan]

National Center for Toxicological Research (NCTR) [USA]

National Institute for Clinical Excellence (NICE) [UK]

National Patient Safety Agency (NPSA)

NDA

NDA Regulatory Science

Novartis

Office of Prescription Medicines [Australia]

Office of Regulatory Affairs (ORA) [USA]

Office of the Commissioner (OC) [USA]

Oracle

Pan American Network for Drug Regulatory Harmonisation (PANDRH)

Pfizer

Pharmaceutical and Medical Devices Agency (PMDA) [Japan]

Pharmaceutical Research and Manufacturers of America (PhRMA)

Pharmaceuticals and Biologics Branch (Health Sciences Authority) [Singapore]

PharSafer Associates 

Phase Forward

PrimeVigilance 

PROTECT (Pharmacoepidemiological Research on Outcomes of Therapeutics by a European Consortium)

Quintiles Transnational 

Roche 

Sanofi

SaPhar

Serious Adverse Event Consortium 

Southern African Development Community (SADC)

State Food and Drug Administration [China]

Tata Consultancy Services

The White House Office of National Drug Control Policy

The Observer

UK Government 

Uppsala Monitoring Centre (UMC)

US Federal Government

VIGOR Study

WHO Collaborating Centre for International Drug Monitoring

World Health Organization (WHO) 

To order this report:

: Pharmacovigilance and Related Developments 2011-2021

More  Market Research Report

Check our  Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.